Fountzilas, Elena http://orcid.org/0000-0002-4884-2544
Lampaki, Sofia
Koliou, Georgia-Angeliki
Koumarianou, Anna
Levva, Sofia
Vagionas, Anastasios
Christopoulou, Athina
Laloysis, Athanasios
Psyrri, Amanda
Binas, Ioannis
Mountzios, Giannis
Kentepozidis, Nikolaos
Kotsakis, Athanassios
Saloustros, Emmanouil
Boutis, Anastasios
Nikolaidi, Adamantia
Fountzilas, George
Georgoulias, Vassilis
Chrysanthidis, Miltiadis
Kotteas, Elias
Vo, Henry
Tsiatas, Marinos
Res, Eleni
Linardou, Helena
Daoussis, Dimitrios
Bompolaki, Iliada
Andreadou, Anna
Papaxoinis, George
Spyratos, Dionisios
Gogas, Helen
Syrigos, Konstantinos N.
Bafaloukos, Dimitrios
Funding for this research was provided by:
Hellenic Society of Medical Oncology
Hellenic Cooperative Oncology Group (TR21/AI)
Article History
Received: 2 April 2021
Accepted: 8 June 2021
First Online: 23 June 2021
Declarations
:
: EF: Advisory Role: LEO Pharma. Speaker fees: Roche, Pfizer, AstraZeneca. Stock ownership: GENPREX INC, Deciphera Pharmaceuticals, Inc. Travel grant: Merck, Pfizer, and K.A.M Oncology/Hematology and DEMO. AK: Advisory Role: Genesis Pharma. Honoraria: Pfizer. Speaker’s bureau: Roche. Research Funding: Merck. Travel: MSD. AK: educational grants: Novartis, Pfizer, Merck, Roche, BMS, MSD, Genesis, and Ipsen. AP: Consultation Fees: Amgen, Merck Serono, Roche, BMS, AstraZeneca, MSD. Honoraria: Amgen, Merck Serono, Roche, BMS, AstraZeneca, MSD. Research funds: BMS, Kura. GM: Honoraria/Consultancy: AstraZeneca, Roche, Pfizer, BMS, MSD, Takeda, Boehringer, Merck, Novartis, Amgen, Travel Fees: AstraZeneca, Roche, Pfizer, BMS, MSD, Takeda, Boehringer, Merck, Novartis, Astellas, Pierre Fabre. AK: Consulting or advisory role: Amgen, Roche, BMS, AstraZeneca, MSD, IPSEN. AN: Advisory Board and Speaker fees: Pfizer, Novartis. GF: Advisory Board of Pfizer, Novartis and Roche. Honoraria from AstraZeneca, Genprex stock, Daiichi Sankyo stock. ARIAD stock. RFL Holdings. FORMYCON. HG: Advisory Role: Bristol-Myers Squibb, MSD Oncology, Amgen, Novartis, Roche, Pierre Fabre, Honoraria: Bristol-Myers Squibb, MSD Oncology, Roche, Amgen, Novartis, Research Funding: Bristol-Myers Squibb, Roche, MSD Oncology, Travel: Roche, Bristol-Myers Squibb. The rest of the authors declare no conflict of interest.
: The study was approved by the Institutional Review Board of “G. Papanikolaou” General Hospital (protocol number: 339_4/3/2021).
: All authors have agreed to participate in this article and have given their consent for publication.